Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Pruritus | Review

Evaluation, management and future perspectives of anal pruritus: a narrative review

Authors: Matas Jakubauskas, Audrius Dulskas

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Purpose

The without a time limitation. Most recent search was performed on 1st June 2022.

Results

Thorough history and physical examination are very important in view of multiple possible causes of anal pruritus. Most of the focus during examination is drawn on to the perianal region. A digital rectal examination and an anoscopy are essential. It is necessary aim of this narrative review is to overview the classification, diagnostics, possible treatment options and future perspective of anal pruritus.

Methods

The search was performed by two authors (AD and MJ) independently in the following electronic databases: PubMed, EMBASE, Web of Science, Cochrane Library, CENTRAL and the Allied and Complementary Medicine Databases (AMED). Search was restricted to English language only to avoid moisture and the use of soaps in the perianal region. Furthermore, the patient should avoid certain foods and increase the intake of fiber. If the symptoms do not resolve, topical steroids, capsaicin (0.006%) and tacrolimus (0.1%) ointments may be used. For intractable cases, intradermal methylene blue injection might give a long-lasting symptom relief.

Conclusion

Anal pruritus is a long-term deteriorating quality of life issue. Most of the time it is a symptom with a difficult diagnosis. Thorough history and examination should be performed for the best possible treatment.

Hanno R, Murphy P. Pruritus ani. Classif manag Dermatol Clin. 1987;5:811–6. https://doi.org/10.1016/S0733-8635(18)30725-3.CrossRef

Laurent A, Boucharlat J, Bosson JL, et al. Psychological assessment of patients with idiopathic pruritus ani. Psychother Psychosom. 1997;66:163–6. https://doi.org/10.1159/000289128.CrossRef

Hadasik K, Arasiewicz H, BrzezińskaWcisło L. Assessment of the anxiety and depression among patients with idiopathic pruritus ani. Psychother. 2021;38:689–93. https://doi.org/10.5114/ada.2021.108906.CrossRef

Umanskiy K, Messaris E, et al. Dermatology and Pruritus Ani. In: Steele SR, Hull TL, Hyman N, et al., editors. The ASCRS textbook of colon and rectal surgery. Berlin: Springer International Publishing; 2022. p. 311–22.CrossRef

Griffiths CEM, Barker J, Bleiker TO, et al. Dermatoses of Perineal and Perianal Skin In Rook’s Textbook of Dermatology 9th Edition. 9th ed. Hoboken: Wiley Blackwell Publishing; 2016. p. 1131–11333.CrossRef

Ortega AE, Delgadillo X. Idiopathic pruritus ani and acute perianal dermatitis. Clin Colon Rectal Surg. 2019;32:327–32. https://doi.org/10.1055/s-0039-1687827.CrossRef

Allan A, Ambrose NS, Silverman S, Keighley MR. Physiological study of pruritus ani. Br J Surg. 1987;74:576–9. https://doi.org/10.1002/bjs.1800740710.CrossRef

Farouk R, Duthie GS, Pryde A, Bartolo DCC. Abnormal transient internal sphincter relaxation in idiopathic pruritus ani: physiological evidence from ambulatory monitoring. Br J Surg. 2005;81:603–6. https://doi.org/10.1002/bjs.1800810442.CrossRef

Daniel GL, Longo WE, Vernava AM. Pruritus ani: causes and concerns. Dis Colon Rectum. 1994;37:670–4. https://doi.org/10.1007/BF02054410.CrossRef

10.

Siddiqi S, Vijay V, Ward M, et al. Pruritus Ani. Annals. 2008;90:457–63. https://doi.org/10.1308/003588408X317940.CrossRef

11.

Nasseri YY, Osborne MC. Pruritus ani. Gastroenterol Clin North Am. 2013;42:801–13. https://doi.org/10.1016/j.gtc.2013.09.002.CrossRef

12.

Cohen AD, Vander T, Medvendovsky E, et al. Neuropathic scrotal pruritus. J Am Acad Dermatol. 2005;52:61–6. https://doi.org/10.1016/j.jaad.2004.04.039.CrossRef

13.

Havlickova B, Weyandt GH. Therapeutic management of anal eczema: an evidence-based review. Int J Clin Pract. 2014;68:1388–99. https://doi.org/10.1111/ijcp.12457.CrossRef

14.

Markell KW, Billingham RP. Pruritus ani: etiology and management. Surg Clin North Am. 2010;90:125–35. https://doi.org/10.1016/j.suc.2009.09.007.CrossRef

15.

Smith LE, Henrichs D, McCullah RD. Prospective studies on the etiology and treatment of pruritus ani. Dis Colon Rectum. 1982;25:358–63. https://doi.org/10.1007/BF02553616.CrossRef

16.

Ibarra J. Threadworms: a starting point for family hygiene. Br J Community Nurs. 2001;6:414–20. https://doi.org/10.12968/bjcn.2001.6.8.7058.CrossRef

17.

Goldman L, Kitzmiller KW. Perianal atrophoderma from topical corticosteroids. Arch Dermatol. 1973;107:611–2. https://doi.org/10.1001/archderm.1973.01620190083022.CrossRef

18.

Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36:77–97. https://doi.org/10.1007/BF02050307.CrossRef

19.

Beck DE, Wexner SD, Rafferty JF. Perianal Dermatologic Disease. In: Gordon and Nivatvongs’ Principles and Practice of Surgery for the Colon, Rectum, and Anus. 4th ed. New York: Thieme Medical Publishers; 2018. p. 222–37.

20.

Kränke B, Trummer M, Brabek E, et al. Etiologic and causative factors in perianal dermatitis: results of a prospective study in 126 patients. Wien Klin Wochenschr. 2006;118:90–4. https://doi.org/10.1007/s00508-006-0529-x.CrossRef

21.

Maisonneuve P, Botteri E, Lowenfels AB. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. Gastroenterology. 2008;135:710. https://doi.org/10.1053/j.gastro.2008.04.039.CrossRef

22.

Abu-Asi MJ, White IR, McFadden JP, White JML. Patch testing is clinically important for patients with peri-anal dermatoses and pruritus ani. Contact Dermatitis. 2016;74:298–300. https://doi.org/10.1111/cod.12514.CrossRef

23.

Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87:291–4. https://doi.org/10.2340/00015555-0305.CrossRef

24.

Kuehn HG, Gebbensleben O, Hilger Y, Rohde H. Relationship between anal symptoms and anal findings. Int J Med Sci. 2009. https://doi.org/10.7150/ijms.6.77.CrossRef

25.

Ansari P. Pruritus ani. Clin Colon Rectal Surg. 2016;29:038–42. https://doi.org/10.1055/s-0035-1570391.CrossRef

26.

Tomi N, Weiser R, Strohal R, Mittlboeck M. A liquid-film forming acrylate cream for the treatment of anal pruritus. Br J Nurs. 2012;21:98–102. https://doi.org/10.12968/bjon.2012.21.2.98.CrossRef

27.

Weyandt G, Breitkopf C, Werner RN, et al. German S1 guidelines for the diagnosis and treatment of perianal dermatitis (anal eczema). J Deutsche Derma Gesell. 2020;18:648–57. https://doi.org/10.1111/ddg.14125.CrossRef

28.

Murie JA, Sim AJ, Mackenzie I. The importance of pain, pruritus and soiling as symptoms of haemorrhoids and their response to haemorrhoidectomy or rubber band ligation. Br J Surg. 1981;68:247–9. https://doi.org/10.1002/bjs.1800680409.CrossRef

29.

Brunner MJ. Pruritus ani and anal hygiene. Arch Dermatol. 1960;82:267. https://doi.org/10.1001/archderm.1960.01580020109028.CrossRef

30.

Oztas MO. Idiopathic perianal pruritus: washing compared with topical corticosteroids. Postgrad Med J. 2004;80:295–7. https://doi.org/10.1136/pgmj.2003.013045.CrossRef

31.

Shocket E. Anal cleansing vs. irritation. Dis Colon Rectum. 2000;43:1176–7. https://doi.org/10.1007/BF02236575.CrossRef

32.

Jensen SL. A randomised trial of simple excision of non-specific hypertrophied anal papillae versus expectant management in patients with chronic pruritus ani. Ann R Coll Surg Engl. 1988;70:348–9.

33.

Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother. 2010;11:1673–82. https://doi.org/10.1517/14656566.2010.484420.CrossRef

34.

Anand P. Capsaicin and menthol in the treatment of itch and pain: recently cloned receptors provide the key. Gut. 2003;52:1233–5. https://doi.org/10.1136/gut.52.9.1233.CrossRef

35.

Al-Ghnaniem R, Short K, Pullen A, et al. 1% Hydrocortisone ointment is an effective treatment of pruritus ani: a pilot randomized controlled crossover trial. Int J Colorectal Dis. 2007;22:1463. https://doi.org/10.1007/s00384-007-0325-8.CrossRef

36.

Suys E. Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. J Am Acad Dermatol. 2012;66:327–8. https://doi.org/10.1016/j.jaad.2011.05.024.CrossRef

37.

Hercogová J. Topical anti-itch therapy: topical anti-itch therapy. Dermatol Ther. 2005;18:341–3. https://doi.org/10.1111/j.1529-8019.2005.00033.x.CrossRef

38.

Kirsner RS, Heffernan MP, Antaya R. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids. Acta Derm Venereol. 2010;90:58–64. https://doi.org/10.2340/00015555-0748.CrossRef

39.

Lysy J. Topical capsaicin—a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study. Gut. 2003;52:1323–6. https://doi.org/10.1136/gut.52.9.1323.CrossRef

40.

Samalavicius NE, Klimasauskiene V, Dulskas A. Intradermal 1% methylene blue injection for intractable idiopathic pruritus ani—a video vignette. Colorectal Dis. 2020;22:846–7. https://doi.org/10.1111/codi.14997.CrossRef

41.

Eusebio EB, Graham J, Mody N. Treatment of intractable pruritus ani. Dis Colon Rectum. 1990;33:770–2. https://doi.org/10.1007/BF02052324.CrossRef

42.

Samalavicius NE, Poskus T, Gupta RK, Lunevicius R. Long-term results of single intradermal 1 % methylene blue injection for intractable idiopathic pruritus ani: a prospective study. Tech Coloproctol. 2012;16:295–9. https://doi.org/10.1007/s10151-012-0846-1.CrossRef

43.

Kim JH, Kim DH, Lee YP. Long-term follow-up of intradermal injection of methylene blue for intractable, idiopathic pruritus ani. Tech Coloproctol. 2019;23:143–9. https://doi.org/10.1007/s10151-019-01934-x.CrossRef

44.

Botterill ID, Sagar PM. Intra-dermal methylene blue, hydrocortisone and lignocaine for chronic, intractable pruritus ani. Colorect Dis. 2002;4:144–6. https://doi.org/10.1046/j.1463-1318.2002.00329.x.CrossRef

45.

Fransiska D, Jeo WS, Moenadjat Y, Friska D. Methylene blue effectiveness as local analgesic after anorectal surgery: a literature review. Adv Med. 2017;2017:1–5. https://doi.org/10.1155/2017/3968278.CrossRef

46.

Kim BS. The translational revolution of itch. Neuron. 2022. https://doi.org/10.1016/j.neuron.2022.03.031.CrossRef

47.

Misery L, Brenaut E, Pierre O, et al. Chronic itch: emerging treatments following new research concepts. Br J Pharmacol. 2021;178:4775–91. https://doi.org/10.1111/bph.15672.CrossRef

48.

Fourzali K, Golpanian RS, Yosipovitch G. Dupilumab use in atopic dermatitis and beyond in skin diseases. Immunotherapy. 2020;12:1221–35. https://doi.org/10.2217/imt-2020-0175.CrossRef

49.

Gael M, Adam T, Mariano-Bourin M, Bursztejn Ac. Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors. Acad Dermatol Venereol jdv. 2022. https://doi.org/10.1111/jdv.18221.CrossRef

50.

Calugareanu A, Jachiet M, Tauber M, et al. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. J Eur Acad Dermatol Venereol. 2020;34:e74–6. https://doi.org/10.1111/jdv.15957.CrossRef

51.

Jeon J, Wang F, Badic A, Kim BS. Treatment of patients with chronic pruritus of unknown origin with dupilumab. J Dermatol Treat. 2021. https://doi.org/10.1080/09546634.2021.1880542.CrossRef

52.

Bonnekoh H, Butze M, Metz M. Characterization of the effects on pruritus by novel treatments for atopic dermatitis. J Deutsche Derma Gesell. 2022;20:150–6. https://doi.org/10.1111/ddg.14678.CrossRef

53.

Roh YS, Choi J, Sutaria N, et al. IL-31 inhibition as a therapeutic approach for the management of chronic pruritic dermatoses. Drugs. 2021;81:895–905. https://doi.org/10.1007/s40265-021-01521-1.CrossRef

54.

Kabashima K, Matsumura T, Komazaki H, Kawashima M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383:141–50. https://doi.org/10.1056/NEJMoa1917006.CrossRef

55.

Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382:706–16. https://doi.org/10.1056/NEJMoa1908316.CrossRef

56.

Levy G, Guglielmelli P, Langmuir P, Constantinescu S. JAK inhibitors and COVID-19. J Immunother Cancer. 2022;10:e002838. https://doi.org/10.1136/jitc-2021-002838.CrossRef

57.

Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133–45. https://doi.org/10.1038/s41584-021-00726-8.CrossRef

58.

Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58:1755–66. https://doi.org/10.1093/rheumatology/kez087.CrossRef

59.

Simpson EL, Lacour J-P, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242–55. https://doi.org/10.1111/bjd.18898.CrossRef

60.

Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384:1101–12. https://doi.org/10.1056/NEJMoa2019380.CrossRef

61.

Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. The Lancet. 2021;397:2151–68. https://doi.org/10.1016/S0140-6736(21)00588-2.CrossRef

62.

Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase II a randomized trial. Br J Dermatol. 2016;175:902–11. https://doi.org/10.1111/bjd.14871.CrossRef

63.

Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82:823–31. https://doi.org/10.1016/j.jaad.2019.12.015.CrossRef

64.

Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82:1305–13. https://doi.org/10.1016/j.jaad.2020.02.009.CrossRef

65.

Elmariah S, Chisolm S, Sciascia T, Kwatra SG. Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: a review of basic science and clinical implications. JAAD Int. 2022;7:156–63. https://doi.org/10.1016/j.jdin.2022.03.007.CrossRef

66.

Lee J, Shin JU, Noh S, et al. Clinical efficacy and safety of naltrexone combination therapy in older patients with severe pruritus. Ann Dermatol. 2016;28:159. https://doi.org/10.5021/ad.2016.28.2.159.CrossRef

67.

Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382:222–32. https://doi.org/10.1056/NEJMoa1912770.CrossRef

68.

Deeks ED. Difelikefalin: first approval. Drugs. 2021;81:1937–44. https://doi.org/10.1007/s40265-021-01619-6.CrossRef

69.

Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25:1251–7. https://doi.org/10.1093/ndt/gfp588.CrossRef

70.

Mathur VS, Kumar J, Crawford PW, et al. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. Am J Nephrol. 2017;46:450–8. https://doi.org/10.1159/000484573.CrossRef

71.

Weisshaar E, Szepietowski JC, Bernhard JD, et al. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase. Acad Dermatol Venereol. 2022;36:453–61. https://doi.org/10.1111/jdv.17816.CrossRef

Title: Evaluation, management and future perspectives of anal pruritus: a narrative review
Authors: Matas Jakubauskas
Audrius Dulskas
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Pruritus
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01018-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation, management and future perspectives of anal pruritus: a narrative review

Abstract

Purpose

Results

Methods

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Results

Methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Adjuvant chemoradiotherapy vs chemotherapy for resectable biliary tract cancer: a propensity score matching analysis based on the SEER database

Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators

Application of mesohepatectomy with caudate lobectomy for the treatment of type III–IV hilar cholangiocarcinoma: a single-center retrospective study

Prognosis of coronary heart disease after percutaneous coronary intervention: a bibliometric analysis over the period 2004–2022

Development and testing of a random forest-based machine learning model for predicting events among breast cancer patients with a poor response to neoadjuvant chemotherapy

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials